X

Vous n'êtes pas connecté

Rubriques :

Maroc Maroc - WN.COM - Health - 30/Sep 04:27

FDA Approves Opzelura for Atopic Dermatitis in Children

MONDAY, Sept. 29, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opzelura cream 1.5 percent (ruxolitinib) for children ages 2 to 11 years with atopic dermatitis (AD). ......

Articles similaires

Sorry! Image not available at this time

FDA Approves Opzelura for Atopic Dermatitis in Children

wn.com - 30/Sep 08:38

MONDAY, Sept. 29, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opzelura cream 1.5 percent (ruxolitinib) for children...

Sorry! Image not available at this time

FDA Approves Opzelura for Atopic Dermatitis in Children

drugs.com - 29/Sep 20:05

MONDAY, Sept. 29, 2025 -- The U.S. Food and Drug Administration has approved Opzelura cream 1.5 percent (ruxolitinib) for children ages 2 to 11 years...

Sorry! Image not available at this time

FDA Approves Zoryve for Atopic Dermatitis in Young Children

drugs.com - 18:52

THURSDAY, Oct. 9, 2025 -- The U.S. Food and Drug Administration has approved the supplemental new drug application for Zoryve (roflumilast) cream...

Sorry! Image not available at this time

FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

healthtechzone.com - 06/Oct 12:00

Sorry! Image not available at this time

FDA Approves Tremfya for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis

wn.com - 03/Oct 07:27

THURSDAY, Oct. 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of plaque...

Sorry! Image not available at this time

FDA Approves Tremfya (guselkumab) for the Treatment of Pediatric Plaque Psoriasis and Active Psoriatic Arthritis

drugs.com - 29/Sep 21:09

HORSHAM, PA, (September 29, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has...

Sorry! Image not available at this time

FDA Approves Tremfya (guselkumab) for the Treatment of Pediatric Plaque Psoriasis and Active Psoriatic Arthritis

drugs.com - 29/Sep 21:09

HORSHAM, PA, (September 29, 2025) – Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has...

Sorry! Image not available at this time

FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

drugs.com - 06/Oct 19:10

WESTLAKE VILLAGE, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical...

Sorry! Image not available at this time

FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

drugs.com - 06/Oct 19:10

WESTLAKE VILLAGE, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical...

Sorry! Image not available at this time

FDA Approves Tremfya for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis

drugs.com - 02/Oct 21:28

THURSDAY, Oct. 2, 2025 -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for the treatment of plaque psoriasis and active...

Les derniers communiqués